DOCSLIB.ORG

Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation de Andrade Mello, Paola, Robson Coutinho-Silva, and Luiz Eduardo Baggio Savio. 2017. “Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives.” Frontiers in Immunology 8 (1): 1526. doi:10.3389/fimmu.2017.01526. http://dx.doi.org/10.3389/ fimmu.2017.01526. Published Version doi:10.3389/fimmu.2017.01526 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493041 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA REVIEW published: 14 November 2017 doi: 10.3389/fimmu.2017.01526 Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives Paola de Andrade Mello1, Robson Coutinho-Silva 2* and Luiz Eduardo Baggio Savio2* 1 Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States, 2Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil Cancer is still one of the world’s most pressing health-care challenges, leading to a high number of deaths worldwide. Immunotherapy is a new developing therapy that Edited by: boosts patient’s immune system to fight cancer by modifying tumor–immune cells Salem Chouaib, interaction in the tumor microenvironment (TME). Extracellular adenosine triphosphate Institut Gustave Roussy, France (eATP) and adenosine (Ado) are signaling molecules released in the TME that act Reviewed by: Alessandro Poggi, as modulators of both immune and tumor cell responses. Extracellular adenosine Azienda Ospedaliera Universitaria triphosphate and Ado activate purinergic type 2 (P2) and type 1 (P1) receptors, San Martino (IRCCS), Italy respectively, triggering the so-called purinergic signaling. The concentration of eATP Francois Ghiringhelli, INSERM, France and Ado within the TME is tightly controlled by several cell-surface ectonucleotidases, *Correspondence: such as CD39 and CD73, the major ecto-enzymes expressed in cancer cells, immune Robson Coutinho-Silva cells, stromal cells, and vasculature, being CD73 also expressed on tumor-associated [email protected]; Luiz Eduardo Baggio Savio fibroblasts. Once accumulated in the TME, eATP boosts antitumor immune response, [email protected], while Ado attenuates or suppresses immunity against the tumor. In addition, both [email protected] molecules can mediate growth stimulation or inhibition of the tumor, depending on the specific receptor activated. Therefore, purinergic signaling is able to modulate Specialty section: This article was submitted to both tumor and immune cells behavior and, consequently, the tumor–host interaction Cancer Immunity and and disease progression. In this review, we discuss the role of purinergic signaling Immunotherapy, a section of the journal in the host–tumor interaction detailing the multifaceted effects of eATP and Ado in Frontiers in Immunology the inflammatory TME. Moreover, we present recent findings into the application of Received: 16 September 2017 purinergic-targeting therapy as a potential novel option to boost antitumor immune Accepted: 27 October 2017 responses in cancer. Published: 14 November 2017 Citation: Keywords: purinergic signaling, P2X7 receptor, CD39, CD73, tumor microenvironment, immunotherapy de Andrade Mello P, Coutinho-Silva R and Savio LEB (2017) Multifaceted Effects of Extracellular Adenosine INTRODUCTION Triphosphate and Adenosine in the Tumor–Host Interaction and Cancer is still one of the world’s most pressing health-care challenges, leading to death in an esti- Therapeutic Perspectives. mated number of 600,920 patients per year in the United States (1). However, recent advances in Front. Immunol. 8:1526. cancer immunotherapy have transformed the treatment of several patients, extending and improving doi: 10.3389/fimmu.2017.01526 their lives (2, 3). Immunotherapy is a new developing therapy that boosts patient’s immune system Frontiers in Immunology | www.frontiersin.org 1 November 2017 | Volume 8 | Article 1526 de Andrade Mello et al. Purines Multifaceted Effects in Cancer to fight cancer, by modifying tumor–immune cells interaction in response and Ado attenuates or suppresses immunity on the host the tumor microenvironment (TME) (4). According to the cancer side (38–45), both molecules can mediate growth stimulation or immunoediting concept, the interaction between cancer and inhibition on the tumor cells, depending on the specific receptor immune cells occurs in three essential phases: elimination, equilib- activated (46–52). Regardless, the final effect on tumor growth— rium, and escape—from cancer immune surveillance to immune either beneficial or detrimental—will depend on the eATP/Ado escape (5–7). In the elimination and equilibrium phase innate levels, the panel of P2 and P1 receptors subtypes and CD39/CD73 and adaptive immune system—mainly NK and T cells—mount expression by immune, tumor, and stromal cells in the TME (22). an effective immune response against the highly immunogenic Therefore, despite its complexity and dual behavior, modula- tumors, and allow the less immunogenic ones escape (8–16). This tion of purinergic signaling by targeting eATP/Ado pathways immunologic pressure selects and favors tumor variants resistant appears to be a promising strategy to modify cancer and immune to the immune system to proliferate (immunoevasion) (9, 17). cells cross talk in the TME (24, 36, 53). In this review, we will During this process, both cancer and inflammatory cells release discuss the role of purinergic signaling into the host–tumor several soluble factors such as cytokines, chemokines, growth interaction detailing the multifaceted effects of eATP and Ado factors, matrix-degrading enzymes, and nucleotides that facilitate in the inflammatory TME. Furthermore, we will highlight the tumor immune escape and allow tumor growth, angiogenesis, application of combining purinergic-targeting therapies with invasion, and metastasis (18–22). Therefore, targeting multiple other anticancer treatments as a potential new strategy to over- molecules that avoid immunoevasion and boost antitumor come immune escape, potentiate antitumor immune response, immune responses are the leading paths to successfully treat a and, consequently, restrain tumor growth. whole range of tumor types (3). Among the nucleotides released in the TME, extracellular eATP IN THE TME adenosine triphosphate (eATP) and adenosine (Ado) are potent modulators of both immune and tumor cell response (23, 24). Measurement of eATP levels in different biological context eATP and Ado exert their effects acting through P2 and P1 reveals that healthy tissues present very low levels (10–100 nM) purinergic receptors, respectively, triggering the so-called of this nucleotide in the pericellular space, while in sites of tissue purinergic signaling (25, 26). Purinergic signaling has long damage, inflammation, hypoxia, ischemia, TME or metastases been involved with inflammation and cancer having a pivotal it can reach high levels (hundreds of micromoles per liter) role in modulating cell migration, proliferation, and cell death (24, 54–56). ATP is abundantly released in the extracellular (27, 28). P2 and P1 receptors are expressed by nearly all cell space due to cell death, cell stress, and activation of pannexin/ types (immune and non-immune cells) and differently trigger connexin channels on immune and endothelial cells (54, 57, 58). cell signaling according to their subtypes (29–31). The P2 recep- In these settings, increased levels of eATP are sensed as a “danger tor is subdivided into two separate subfamilies, P2X (P2X1–7) signal” by the innate immune cells resulting in their recruitment ionotropic ion channels receptors and P2Y (P2Y1, P2Y2, to the damaged-tissue site (42, 57, 59–61). Particularly in the P2Y4, P2Y6, and P2Y11–P2Y14) G-protein-coupled receptors TME, eATP acting through P2 receptors boosts the antitumor (25, 26), whereas the P1 receptor family (A1, A2A, A2B, and A3) only immunity at the same time that stimulates endothelial and tumor comprised by G-protein-coupled receptors subtype (32). These cells (27, 36, 42, 48, 60). different purinergic receptors express distinct agonist affinity and specificity, therefore influencing both tumor and immune cells eATP Effect on the Host Side behavior according to the levels of eATP/Ado in TME (33–35). Activation of P2 receptors by eATP shapes various innate and Levels of eATP and Ado are tightly controlled by several adaptive immune responses (30). The P2X and P2Y receptors ectonucleotidases. Among them, CD39 and CD73 are the most expression (either constitutive or upregulated in pathological important ecto-enzymes expressed in cancer cells, regulatory conditions) varies according to the cell type and therefore dictates immune cells and vasculature responsible for modulating puriner- immune cell function, such as metabolism, adhesion, activation, gic signaling within the TME (36, 37). CD39 is a member of the migration, maturation, release of
Load more

Recommended publications
  • Cells Δγ Lineage Choice and Shapes Peripheral Purinergic P2X7
    Purinergic P2X7 Receptor Drives T Cell Lineage Choice and Shapes Peripheral δγ Cells This information is current as Michela Frascoli, Jessica Marcandalli, Ursula Schenk and of October 2, 2021. Fabio Grassi J Immunol 2012; 189:174-180; Prepublished online 30 May 2012; doi: 10.4049/jimmunol.1101582 http://www.jimmunol.org/content/189/1/174 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/05/30/jimmunol.110158 Material 2.DC1 http://www.jimmunol.org/ References This article cites 31 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/189/1/174.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 2, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Purinergic P2X7 Receptor Drives T Cell Lineage Choice and Shapes Peripheral gd Cells Michela Frascoli,* Jessica Marcandalli,* Ursula Schenk,*,1 and Fabio Grassi*,† TCR signal strength instructs ab versus gd lineage decision in immature T cells.
    [Show full text]
  • Extracellular Adenosine Triphosphate and Adenosine in Cancer
    Oncogene (2010) 29, 5346–5358 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW Extracellular adenosine triphosphate and adenosine in cancer J Stagg and MJ Smyth Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Adenosine triphosphate (ATP) is actively released in the mulated the hypothesis of purinergic neurotransmission extracellular environment in response to tissue damage (Burnstock, 1972). Burnstock’s hypothesis that ATP and cellular stress. Through the activation of P2X and could be released by cells to perform intercellular P2Y receptors, extracellular ATP enhances tissue repair, signaling was initially met with skepticism, as it seemed promotes the recruitment of immune phagocytes and unlikely that a molecule that acts as an intracellular dendritic cells, and acts as a co-activator of NLR family, source of energy would also function as an extracellular pyrin domain-containing 3 (NLRP3) inflammasomes. messenger. Nevertheless, Burnstock pursued his work The conversion of extracellular ATP to adenosine, in and, together with Che Su and John Bevan, reported contrast, essentially through the enzymatic activity of the that ATP was also released from sympathetic nerves ecto-nucleotidases CD39 and CD73, acts as a negative- during stimulation (Su et al., 1971). Three decades later, feedback mechanism to prevent excessive immune responses. following the cloning and characterization of ATP and Here we review the effects of extracellular ATP and adenosine adenosine cell surface receptors, purinergic signaling is a on tumorigenesis. First, we summarize the functions of well-established concept and constitutes an expanding extracellular ATP and adenosine in the context of tumor field of research in health and disease, including cancer immunity.
    [Show full text]
  • Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
    cancers Review Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives 1, 1, 1 2 1 Laurence Pellerin y, Lorry Carrié y , Carine Dufau , Laurence Nieto , Bruno Ségui , 1,3 1, , 1, , Thierry Levade , Joëlle Riond * z and Nathalie Andrieu-Abadie * z 1 Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III Paul-Sabatier, Inserm 1037, 2 avenue Hubert Curien, tgrCS 53717, 31037 Toulouse CEDEX 1, France; [email protected] (L.P.); [email protected] (L.C.); [email protected] (C.D.); [email protected] (B.S.); [email protected] (T.L.) 2 Institut de Pharmacologie et de Biologie Structurale, CNRS, Université Toulouse III Paul-Sabatier, UMR 5089, 205 Route de Narbonne, 31400 Toulouse, France; [email protected] 3 Laboratoire de Biochimie Métabolique, CHU Toulouse, 31059 Toulouse, France * Correspondence: [email protected] (J.R.); [email protected] (N.A.-A.); Tel.: +33-582-7416-20 (J.R.) These authors contributed equally to this work. y These authors jointly supervised this work. z Received: 15 September 2020; Accepted: 23 October 2020; Published: 27 October 2020 Simple Summary: Melanoma is a devastating skin cancer characterized by an impressive metabolic plasticity. Melanoma cells are able to adapt to the tumor microenvironment by using a variety of fuels that contribute to tumor growth and progression. In this review, the authors summarize the contribution of the lipid metabolic network in melanoma plasticity and aggressiveness, with a particular attention to specific lipid classes such as glycerophospholipids, sphingolipids, sterols and eicosanoids.
    [Show full text]
  • 500 P2RX7 Agonist Treatment Boosts the Ability of IL-12-Activated CD8+ T
    J Immunother Cancer: first published as 10.1136/jitc-2020-SITC2020.0500 on 10 December 2020. Downloaded from Abstracts homografts and assessed the relationship between CD5 and metastasis, and deregulation of E-cadherin is a hallmark for increased CD69 and PD-1 (markers of T cell activation and epithelial-mesenchymal transition (EMT). exhaustion) by flow cytometry. Methods The study protocol was approved by the Medical Results We report that T cell CD5 levels were higher in CD4 Ethical Committee of the Academic Medical Centre, Amster- + T cells than in CD8+ T cells in 4T1 tumour-bearing mice, dam, The Netherlands (NL42718.018.12). AIMM’s BCL6 and and that high CD5 levels on CD4+ T cells were maintained Bcl-xL immortalization method1 was used to interrogate the in peripheral organs (spleen and lymph nodes). However, both human antibody repertoire. From a carrier of a pathogenic CD4+ and CD8+ T cells recruited to tumours had reduced gene variant in the MSH6 gene diagnosed with stage IV CRC CD5 compared to CD4+ and CD8+ T cells in peripheral and liver metastasis that had been treated with avastin, capeci- organs. In addition, CD5highCD4+ T cells and CD5highCD8 tabine and oxaliplatin, peripheral-blood memory B cells were + T cells from peripheral organs exhibited higher levels of obtained 9 years after last treatment. Antibodies-containing activation and associated exhaustion compared to CD5lowCD4 supernatant of cultured B-cells were screened for binding to 3 + T cell and CD5lowCD8+ T cell from the same organs. different CRC cell lines (DLD1, LS174T and COLO205) and Interestingly, CD8+ T cells among TILs and downregulated absence of binding to fibroblast by flow cytometry.
    [Show full text]
  • Non-Synonymous Single Nucleotide Polymorphisms in the P2X
    Int. J. Mol. Sci. 2014, 15, 13344-13371; doi:10.3390/ijms150813344 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Non-Synonymous Single Nucleotide Polymorphisms in the P2X Receptor Genes: Association with Diseases, Impact on Receptor Functions and Potential Use as Diagnosis Biomarkers Emily A. Caseley 1,†, Stephen P. Muench 1, Sebastien Roger 2, Hong-Ju Mao 3, Stephen A. Baldwin 1 and Lin-Hua Jiang 1,4,†,* 1 School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK; E-Mails: [email protected] (E.A.C.); [email protected] (S.P.M.); [email protected] (S.A.B.) 2 Inserm U1069, University of Tours, Tours 37032, France; E-Mail: [email protected] 3 State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Science, Shanghai 200050, China; E-Mail: [email protected] 4 Department of Physiology and Neurobiology, Xinxiang Medical University, Xinxiang 453003, China † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-0-113-343-4231. Received: 6 June 2014; in revised form: 10 July 2014 / Accepted: 14 July 2014 / Published: 30 July 2014 Abstract: P2X receptors are Ca2+-permeable cationic channels in the cell membranes, where they play an important role in mediating a diversity of physiological and pathophysiological functions of extracellular ATP. Mammalian cells express seven P2X receptor genes. Single nucleotide polymorphisms (SNPs) are widespread in the P2RX genes encoding the human P2X receptors, particularly the human P2X7 receptor.
    [Show full text]
  • Cell Signaling and Regulation of Metabolism Objectives
    Cell Signaling and Regulation of Metabolism Objectives By the end of this lecture, students are expected to: • Differentiate different steps in signaling pathways • Describe the second messenger systems • Recognize the function of signaling pathways for • Signal transmission • Amplification • Discuss the role of signaling pathways in regulation and integration of metabolism No cell lives in isolation • Cells communicate with each other • Cells send and receive information (signals) • Information is relayed within cell to produce a response Signaling Process • Recognition of signal – Receptors • Transduction – Change of external signal into intracellular message with amplification and formation of second messenger • Effect – Modification of cell metabolism and function General Signaling Pathway Signaling Cascades Recognition • Performed by receptors • Ligand will produce response only in cells that have receptors for this particular ligand • Each cell has a specific set of receptors Different Responses to the Same Signaling Molecule. (A) Different Cells Different Responses to the Same Signaling Molecule. (B) One Cell but, Different Pathways Hypoglycemia Glucagon secretion Hepatocyte: Glucagon/receptor binding Second messenger: cAMP Response: Enzyme phosphorylation P P Glycogen synthase Glycogen phosphorylase (Inactive form) (Active form) Inhibition of glycogenesis Stimulation of glycogenolysis GTP-Dependant Regulatory Proteins (G-Proteins) G-Proteins: Trimeric membrane proteins (αβγ) G-stimulatory (Gs) and G-inhibitory (Gi) binds to GTP/GDP
    [Show full text]
  • Upregulation of P2RX7 Incx3cr1-Deficient Mononuclear
    The Journal of Neuroscience, May 6, 2015 • 35(18):6987–6996 • 6987 Neurobiology of Disease Upregulation of P2RX7 in Cx3cr1-Deficient Mononuclear Phagocytes Leads to Increased Interleukin-1␤ Secretion and Photoreceptor Neurodegeneration Shulong J. Hu,1,2,3 Bertrand Calippe,1,2,3 XSophie Lavalette,1,2,3 Christophe Roubeix,1,2,3 Fadoua Montassar,1,2,3 Michael Housset,1,2,3 Olivier Levy,1,2,3 Cecile Delarasse,4 Michel Paques,1,2,3,5 XJose´-Alain Sahel,1,2,3,5 Florian Sennlaub,1,2,3* and XXavier Guillonneau1,2,3* 1INSERM, U 968, Paris F-75012, France, 2Sorbonne Universités, UPMC Univ Paris 06, UMR S 968, Institut de la Vision, Paris, F-75012, France, 3CNRS, UMR 7210, Paris, F-75012, France, 4INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris F-75013, France, and 5Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, DHU ViewMaintain, INSERM-DHOS CIC 1423, Paris, F-75012, France Photoreceptor degeneration in age-related macular degeneration (AMD) is associated with an infiltration and chronic accumulation of mononuclear phagocytes (MPs). We have previously shown that Cx3cr1-deficient mice develop age- and stress- related subretinal accumulation of MPs, which is associated with photoreceptor degeneration. Cx3cr1-deficient MPs have been shown to increase neuronal apoptosis through IL-1␤ in neuroinflammation of the brain. The reason for increased IL-1␤ secretion from Cx3cr1-deficient MPs, and whether IL-1␤ is responsible for increased photoreceptor apoptosis in Cx3cr1-deficient mice, has not been elucidated.
    [Show full text]
  • The Regulatory Role of Key Metabolites in the Control of Cell Signaling
    biomolecules Review The Regulatory Role of Key Metabolites in the Control of Cell Signaling Riccardo Milanesi, Paola Coccetti * and Farida Tripodi Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy; [email protected] (R.M.); [email protected] (F.T.) * Correspondence: [email protected]; Tel.: +39-02-6448-3521 Received: 8 May 2020; Accepted: 3 June 2020; Published: 5 June 2020 Abstract: Robust biological systems are able to adapt to internal and environmental perturbations. This is ensured by a thick crosstalk between metabolism and signal transduction pathways, through which cell cycle progression, cell metabolism and growth are coordinated. Although several reports describe the control of cell signaling on metabolism (mainly through transcriptional regulation and post-translational modifications), much fewer information is available on the role of metabolism in the regulation of signal transduction. Protein-metabolite interactions (PMIs) result in the modification of the protein activity due to a conformational change associated with the binding of a small molecule. An increasing amount of evidences highlight the role of metabolites of the central metabolism in the control of the activity of key signaling proteins in different eukaryotic systems. Here we review the known PMIs between primary metabolites and proteins, through which metabolism affects signal transduction pathways controlled by the conserved kinases Snf1/AMPK, Ras/PKA and TORC1. Interestingly, PMIs influence also the mitochondrial retrograde response (RTG) and calcium signaling, clearly demonstrating that the range of this phenomenon is not limited to signaling pathways related to metabolism. Keywords: Snf1/AMPK/SnRK1; Ras/PKA; TORC1; RTG; calcium; glucose; glycolysis; TCA; amino acids; protein-metabolite interaction 1.
    [Show full text]
  • Identification of a Subset of Immunosuppressive P2RX1
    ARTICLE https://doi.org/10.1038/s41467-020-20447-y OPEN Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis Xu Wang1,2,4, Li-Peng Hu1,4, Wei-Ting Qin1,4, Qin Yang1,4, De-Yu Chen2,4, Qing Li1, Kai-Xia Zhou1, Pei-Qi Huang1, Chun-Jie Xu1, Jun Li1, Lin-Li Yao1, Ya-Hui Wang1, Guang-Ang Tian1, Jian-Yu Yang3, ✉ ✉ ✉ Min-Wei Yang3, De-Jun Liu3, Yong-Wei Sun 3 , Shu-Heng Jiang 1 , Xue-Li Zhang 1 & ✉ Zhi-Gang Zhang 1 1234567890():,; The immunosuppressive microenvironment that is shaped by hepatic metastatic pancreatic ductal adenocarcinoma (PDAC) is essential for tumor cell evasion of immune destruction. Neutrophils are important components of the metastatic tumor microenvironment and exhibit heterogeneity. However, the specific phenotypes, functions and regulatory mechan- isms of neutrophils in PDAC liver metastases remain unknown. Here, we show that a subset of P2RX1-negative neutrophils accumulate in clinical and murine PDAC liver metastases. RNA sequencing of murine PDAC liver metastasis-infiltrated neutrophils show that P2RX1- deficient neutrophils express increased levels of immunosuppressive molecules, including PD-L1, and have enhanced mitochondrial metabolism. Mechanistically, the transcription factor Nrf2 is upregulated in P2RX1-deficient neutrophils and associated with PD-L1 expression and metabolic reprogramming. An anti-PD-1 neutralizing antibody is sufficient to compromise the immunosuppressive effects of P2RX1-deficient neutrophils on OVA- activated OT1 CD8+ T cells. Therefore, our study uncovers a mechanism by which metastatic PDAC tumors evade antitumor immunity by accumulating a subset of immuno- suppressive P2RX1-negative neutrophils. 1 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R.
    [Show full text]
  • Plasma Membrane Receptors for Steroid Hormones in Cell Signaling and Nuclear Function
    Chapter 5 / Plasma Membrane Receptors for Steroids 67 5 Plasma Membrane Receptors for Steroid Hormones in Cell Signaling and Nuclear Function Richard J. Pietras, PhD, MD and Clara M. Szego, PhD CONTENTS INTRODUCTION STEROID RECEPTOR SIGNALING MECHANISMS PLASMA MEMBRANE ORGANIZATION AND STEROID HORMONE RECEPTORS INTEGRATION OF MEMBRANE AND NUCLEAR SIGNALING IN STEROID HORMONE ACTION MEMBRANE-ASSOCIATED STEROID RECEPTORS IN HEALTH AND DISEASE CONCLUSION 1. INTRODUCTION Steroid hormones play an important role in coordi- genomic mechanism is generally slow, often requiring nating rapid, as well as sustained, responses of target hours or days before the consequences of hormone cells in complex organisms to changes in the internal exposure are evident. However, steroids also elicit and external environment. The broad physiologic rapid cell responses, often within seconds (see Fig. 1). effects of steroid hormones in the regulation of growth, The time course of these acute events parallels that development, and homeostasis have been known for evoked by peptide agonists, lending support to the con- decades. Often, these hormone actions culminate in clusion that they do not require precedent gene activa- altered gene expression, which is preceded many hours tion. Rather, many rapid effects of steroids, which have earlier by enhanced nutrient uptake, increased flux of been termed nongenomic, appear to be owing to spe- critical ions, and other preparatory changes in the syn- cific recognition of hormone at the cell membrane. thetic machinery of the cell. Because of certain homo- Although the molecular identity of binding site(s) logies of molecular structure, specific receptors for remains elusive and the signal transduction pathways steroid hormones, vitamin D, retinoids, and thyroid require fuller delineation, there is firm evidence that hormone are often considered a receptor superfamily.
    [Show full text]
  • Increased Gene Copy Number of DEFA1/DEFA3 Worsens Sepsis by Inducing Endothelial Pyroptosis
    Increased gene copy number of DEFA1/DEFA3 worsens sepsis by inducing endothelial pyroptosis QiXing Chena, Yang Yangb, JinChao Houb, Qiang Shua, YiXuan Yinc, WeiTao Fuc, Feng Hanc, TingJun Houc,d, CongLi Zengb, Elizabeta Nemethe, Rose Linzmeiere, Tomas Ganze,1, and XiangMing Fanga,b,1 aDepartment of Clinical Research Center, Children’s Hospital, Zhejiang University School of Medicine, 310052 Hangzhou, China; bDepartment of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003 Hangzhou, China; cCollege of Pharmaceutical Sciences, Zhejiang University, 310058 Hangzhou, China; dInstitute of Functional Nano and Soft Materials, Soochow University, 215123 Suzhou, China; and eDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 Edited by Michael Zasloff, Georgetown University Medical Center, Washington, DC, and accepted by Editorial Board Member Ruslan Medzhitov December 27, 2018 (received for review July 26, 2018) Sepsis claims an estimated 30 million episodes and 6 million deaths The mechanisms causing the quiescent endothelium to develop per year, and treatment options are rather limited. Human barrier dysfunction during sepsis might hold the key to future neutrophil peptides 1–3 (HNP1–3) are the most abundant neutro- therapeutic strategies, but they are still largely unknown. phil granule proteins but their neutrophil content varies because Defensins are short cationic, amphiphilic, cysteine-rich anti- of unusually extensive gene copy number polymorphism. A ge- microbial peptides with three or four intramolecular disulfide netic association study found that increased copy number of the bonds. They are classified as α-, β-, and θ-defensins, of which the HNP-encoding gene DEFA1/DEFA3 is a risk factor for organ dys- first two are the most common human antimicrobial peptides function during sepsis development.
    [Show full text]
  • Cellular Metabolism
    CST SIGNALING PATHWAY DIAGRAMS FOR Cellular Metabolism Insulin Receptor Signaling © 2003–2015 Cell Signaling Technology, Inc. Insulin Receptor SNARE TNF Glucose Complex GLUT4 p85 FlotillinCav PTEN PI3K Gab1 p110 SOCS3 Synip CAP TNFR1 Cbl PIP3 IRS Shc APS SHIP Akt2 SHP-2 PTP1B GLUT4 Crkll EHD1 GRB2 Nck Translocation TC10 C3G EHBP1 IRS-1 Crkll λ/ζ CIP4/2 PKC Fyn SOS PDK1 Rac1 mTORC2 PKCθ GRB10 Jnk GLUT4 PKCλ/ζ IKK vesicle Ras PP2A FFA 14-3-3 LKB1 NO iNOS GLUT4 AS160 Exocytosis Akt ROS c-Raf TBC1D1 AMPK PDK1 14-3-3 TSC2 PDE3B TSC1 Bad SIK2 GSK-3 PRAS40 Rheb [cAMP] MEK1/2 SGK Apoptosis SREBP CBP/p300 mTORC1 PKA Torc2 p70 Erk1/2 PP1 GS Lipin1 4E-BP1 S6K ATP-citrate Degradation ENaC lyase eIF4E HSL Glycogen Synthesis Protein Synthesis, Fatty Acid Growth, and SREBP-1 Sodium Synthesis Proliferation Lipolysis Transport Cytoplasm Erk1/2 SGK Akt2 Fatty Acid and Cholesterol Disruption of Nucleus Synthesis CBP/Torc2/CREB Complex FoxO3 FoxO4 FoxO1 Erk1/2 SREBP LXRα USF Gluconeogenesis Transcription Apoptosis, mTORC1 mTORC2 Autophagy, Lipin1 Glucose and Raptor Sin1 PRR5 GβL Lipid Metabolism Growth mTOR Rictor GβL DEPTOR mTOR DEPTOR Warburg Effect © 2010–2015 Cell Signaling Technology, Inc. Macropinocytosis and other scavenging pathways Glycolysis Growth Factors Glucose Glucose Transporters Ras Hexokinase PI3K Amino Acids NADPH NADP Ras Pentose and Lipids c-Myc Phosphate 6-P- Glucose-6-P Akt Shunt Gluconolactone 6-P- MEK1/2 NADP Ras Amino Acids Gluconate TIGAR Fructose-6-P NADPH p53 LKB1 SREBP PFK Erk1/2 Ribulose-5P AMPK Fructose mTOR Bisphosphate Nucleotide
    [Show full text]